96 related articles for article (PubMed ID: 24969255)
1. Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.
Tadje M
Oncol Nurs Forum; 2014 Jul; 41(4):443-4. PubMed ID: 24969255
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
Bahar MA; Setiawan D; Hak E; Wilffert B
Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.
Daly AK
Drug Metab Pers Ther; 2015 Sep; 30(3):165-74. PubMed ID: 25803091
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
[TBL] [Abstract][Full Text] [Related]
6. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.
Begg EJ; Helsby NA; Jensen BP
Pharmacogenomics; 2012 Jan; 13(1):83-9. PubMed ID: 22176624
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity.
Tukey RH; Strassburg CP; Mackenzie PI
Mol Pharmacol; 2002 Sep; 62(3):446-50. PubMed ID: 12181419
[No Abstract] [Full Text] [Related]
10. Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biol Pharm Bull; 2016; 39(11):1748-1759. PubMed ID: 27803446
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic profile of a central European urban random population-Czech population.
Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
[TBL] [Abstract][Full Text] [Related]
13. A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19.
Ureshino N; Aragane N; Nakamura T; Ide M; Mochinaga S; Fukushima N; Hayashi S; Sueoka E; Kimura S
Oncol Res; 2011; 19(3-4):111-4. PubMed ID: 21473286
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
15. [Irinotecan and liver dysfunctions].
Sablin MP; Le Tourneau C; Faivre S; Raymond E
Therapie; 2007; 62(2):111-5. PubMed ID: 17582311
[TBL] [Abstract][Full Text] [Related]
16. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
17. Role of pharmacogenetics in irinotecan therapy.
de Jong FA; de Jonge MJ; Verweij J; Mathijssen RH
Cancer Lett; 2006 Mar; 234(1):90-106. PubMed ID: 16343744
[TBL] [Abstract][Full Text] [Related]
18. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Lankisch TO; Schulz C; Zwingers T; Erichsen TJ; Manns MP; Heinemann V; Strassburg CP
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):695-701. PubMed ID: 18349289
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
20. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]